^
    1year
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Qurient Co., Ltd. | N=70 --> 130
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Q901
    1year
    Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor (AACR 2023)
    The non-clinical data demonstrate that Q901 not only has a potential as a single agent,but can also be used in combination with other therapeutic strategies to develop next-generation cancer therapeutics to potentially address unmet medical needs.
    Clinical • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • BRCA (Breast cancer early onset)
    |
    ER positive • HR positive • BRCA wild-type
    |
    Q901
    over1year
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Q901
    almost2years
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Qurient Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Q901